Status:
UNKNOWN
Personalizing Aspirin Therapy in Peripheral Arterial Disease Patients
Lead Sponsor:
Unity Health Toronto
Collaborating Sponsors:
University of Toronto
Conditions:
Peripheral Arterial Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Antiplatelet therapies are important to decrease the morbidity and mortality associated with Peripheral Arterial Disease (PAD) through the prevention of thrombus formation. Aspirin (ASA) is a readily ...
Eligibility Criteria
Inclusion
- Self-reported intake of either 81 mg of aspirin per day for 3 or more days
- Diagnosed with peripheral arterial disease
Exclusion
- Alcohol ingestion 24 hours prior to blood draw
- Patients receiving glycoprotein (GP) IIb/IIIa antagonists
- Ingestion of a non steroidal anti-inflammatory drug 3 days prior to blood draw
- History of bleeding disorders
- Gastrointestinal bleeding
- Hemorrhagic stroke
- Allergy to aspirin or ticagrelor
- Pregnancy, thrombocytopenia anmia or leukopenia
Key Trial Info
Start Date :
November 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2021
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04269863
Start Date
November 1 2020
End Date
November 1 2021
Last Update
October 26 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.